Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
January 24 2024 - 8:00AM
Business Wire
- Multi-year collaboration allows GSK to leverage Elegen’s
cell-free synthetic DNA production technology.
- Agreement provides Elegen up to $35 million in near-term
financial and development support and fees, in addition to sales of
ENFINIA™ DNA and a potential equity investment in Elegen by
GSK.
Elegen, a leader in DNA manufacturing innovation, today
announced a collaboration and licensing agreement with GSK
(LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free
DNA manufacturing technology in the development of GSK’s vaccines
and medicines.
The terms of the agreement include upfront fees and purchase
commitments of Elegen’s ENFINIA DNA to support GSK’s development of
medicines and vaccines, including RNA vaccines. Elegen is also
eligible to receive both near-term milestone payments relating to
the development of new product features and a potential equity
investment in Elegen by GSK.
Commercially launched in March of last year, ENFINIA DNA
delivers NGS-verified, high-complexity, clonal-quality, linear DNA
up to 7kb in as fast as seven business days. Unlike conventional
synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is
produced entirely cell-free, with the potential to enable a
seamless transition from discovery to clinical scale-up under GMP.
This technology may save significant time and substantial resources
spent iteratively cloning, linearizing and purifying plasmid DNA as
well as generating master cell banks. Elegen’s innovation in
cell-free DNA manufacturing technology represents a significant
leap forward that could power the next generation of mRNA, cell and
gene therapies.
This collaboration follows the Early Access Program launched by
Elegen in May of last year that offered DNA of longer length and
higher complexity to select customers. “Over the past year dozens
of customers, including multiple top 10 biopharma, have validated
the unprecedented speed, length, accuracy and complexity of our
cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D.,
Elegen founder and CEO. “GSK recognizes the importance of a
reliable, turnkey supply of DNA for a variety of applications for
which speed, accuracy and quality of DNA synthesis are essential.
This collaboration will expand our offering to include the clinical
production of genetic medicines potentially including mRNA, cell
and viral gene therapies.”
About Elegen
Elegen is bringing unique insights and technical innovation to
create high-quality synthetic DNA faster, catalyzing the next
revolution in the life sciences. The company is led by seasoned
leaders with decades of experience developing novel and scalable
approaches in molecular biology, chemistry and microfluidics.
Elegen uses a proprietary microfluidics approach to build longer,
higher-quality DNA on a faster timeline for agricultural, chemical,
healthcare and pharma industries. Founded in 2017, Elegen is
privately held and based in the San Francisco Bay Area. For more
information, visit elegenbio.com and connect with us on LinkedIn
and X (Twitter).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124105579/en/
ELEGEN CONTACT Randy Dyer Vice President of Marketing, Elegen
randy.dyer@elegenbio.com (650) 787-0408
MEDIA CONTACT Joleen Rau Rau Communications
jrau@raucommunications.com (608) 209-0792
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024